Skip to main content
SpringerLink
Log in
Book cover

Alzheimer's Disease pp 45–61Cite as

Advances in Methodology and Current Prospects for Primary Drug Therapies for Alzheimer's Disease

  • Protocol

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 32))

Abstract

There has been gratifying progress in the development of drugs for Alzheimer’s disease (AD). Even though the current generation of medications, the cholinesterase inhibitors (CEIs), has produced only modest benefits, our concept of an “effective” therapy has matured considerably over this time. A less visible but equally important advance has been a quantum leap in expertise in clinical trial methodology. This chapter reviews the methodological underpinnings of clinical trials in AD: patient selection issues, key design issues, and an overview of currently available agents and the prospects for drugs of the future.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, A. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944.

    CAS  PubMed  Google Scholar 

  2. Gearing, M., Mirra, S. S., Hedreen, J. C., Sumi, S. M., Hansen, L. A., and Heyman, A. (1995) The consortium to establish a registry for Alzheimer’s Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology 45,461–466.

    CAS  PubMed  Google Scholar 

  3. Hulette, C., Nochlin, D., McKeel, D., Morris, J. C., Mirra, S. S., Sumi, S. M., and Heyman, A. (1997) Clinical-neuropathological findings in multi-infarct dementia: a report of six autopsied cases. Neurology 48, 668–672.

    CAS  PubMed  Google Scholar 

  4. Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C., and Merskey, H. (1987) The clinical diagnosis of Alzheimer’s disease. Arch. Neurol. 44, 24–29.

    CAS  PubMed  Google Scholar 

  5. Hansen, L. and Samuel, W. (1997) Criteria for Alzheimer Disease and the nosology of dementia with Lewy bodies. Neurology 48, 126–132.

    CAS  PubMed  Google Scholar 

  6. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975) “Mini-mental state”: a practical method for grading the cognitive status of patients for the clinician. J. Psychiatr. Res. 12,189–198.

    Article  CAS  PubMed  Google Scholar 

  7. Petersen, R. C., Smith, G. E., Ivnik, R. J., Tangalos, E. G., Schaid, D. J., Thibodeau, S. N., et al. (1995) Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 273,1274–1278.

    Article  CAS  PubMed  Google Scholar 

  8. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N. Engl. J. Med. 336,1216–1222.

    Article  CAS  PubMed  Google Scholar 

  9. Morris, J. C. (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412–2414.

    CAS  PubMed  Google Scholar 

  10. Leber, P. (1997) Slowing the progression of Alzheimer disease: methodological issues. Alzheimer Dis Assoc Disord 11(Suppl. 5), S10–S21.

    PubMed  Google Scholar 

  11. Rother, M. (1998) Long term efficacy and safety of propentofyllene in patients with Alzheimer’s disease-results of an 18 month placebo controlled trial. Neurobiol. Aging 19(Suppl. 4), S176.

    Google Scholar 

  12. Rosen W. G., Mohs R. C., and Davis, K. L. (1984) Anew rating scale for Alzheimer’s disease. Am. J. Psychiatry 141, 1356–1364.

    CAS  PubMed  Google Scholar 

  13. Knopman, D. and Gracon, S. (1994) Observations on the short-term “natural history” of probable Alzheimer’s disease in a controlled clinical trial. Neurology 44,260–265.

    CAS  PubMed  Google Scholar 

  14. DeKosky, S. T. and Scheff, S. W. (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol. 27,457-64.

    Google Scholar 

  15. Reed, B. R., Jagust, W. J., and Seab, J. P. (1989) Mental status as a predictor of daily function in progressive dementia. Gerontologist 29, 804–807.

    CAS  PubMed  Google Scholar 

  16. Heyman, A., Peterson, B., Fillenbaum, G., and Pieper, C. (1997) Predictors of time to institutionalization of patients with Alzheimer’s disease: the CERAD experience, part XVII. Neurology 48,1304–1309.

    CAS  PubMed  Google Scholar 

  17. Knopman, D. S., Knapp, M. J., Gracon, S. I., and Davis, C. S. (1994) The clinician interview-based impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology 44,2315–2321.

    CAS  PubMed  Google Scholar 

  18. Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., et al. (1997) Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical global impression of change (ADCS-CGIC). Alzheimer Dis. Assoc. Disord. 11(Suppl. 2), S22–S32.

    Article  PubMed  Google Scholar 

  19. Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., and Ferris, S. (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis. Assoc. Disord. 11(Suppl. 2), S33–S39.

    Article  PubMed  Google Scholar 

  20. Reisberg, B., Ferris, S. H., deLeon, M. J., and Crook, T. (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139, 1136–1139.

    CAS  PubMed  Google Scholar 

  21. Galasko, D., Edland, S. D., Morris, J. C., Clark, C., Mohs, R., and Koss, E. (1995) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer’s disease followed over 3 years. Neurology 45, 1451–1455.

    CAS  PubMed  Google Scholar 

  22. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., and Gornbein, J. (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314.

    CAS  PubMed  Google Scholar 

  23. Morris, J. C., Cyrus, P. A., Orazem, J., et al. (1998) Effects of metrifonate on the cognitive, global and behavioral function of Alzheimer’s disease patients: results of a randomized, double-blind, placebo-controlled study. Neurology 50,1222–1230.

    CAS  PubMed  Google Scholar 

  24. Davis, K., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., et al. (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N. Engl. J. Med. 327,1253–1259.

    Article  CAS  PubMed  Google Scholar 

  25. Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., and Gracon, S. I. (1994) A 30-wk randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 271, 985–991.

    Article  CAS  PubMed  Google Scholar 

  26. Rogers, S. L., Farlow, M. R., Doody,. S., Mohs, R., Friedhoff, L. T., and the Donepezil Study Group. (1998) A 24 week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50,136–145.

    CAS  PubMed  Google Scholar 

  27. Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 318, 633–649.

    CAS  PubMed  Google Scholar 

  28. Corey-Brown, J., Anand, R., and Veach, J. (1998) ENA713 (rivastigmine tar-trate), a new acetycholinesterone inhibitor, in patients with mild to moder-ately severe Alzheimer’s disease. Int. J. Geriatric Psychopharmacol. 1, 55–65.

    Google Scholar 

  29. Burns, A., Rossor, M. Hecker, J., Gauthier, S., Petit, H. Miller, H., Roger, S. L., et al.(1999) The effects of Donepezil in Alzheimer’s disease-results from a multination trial. Dement. Geriat. Cogn. Disord. 10, 237–244.

    Article  CAS  Google Scholar 

  30. Davis, K. L. and Powchik, P. (1995) Tacrine. Lancet 345, 625–630.

    Article  CAS  PubMed  Google Scholar 

  31. Bryson, H. M. and Benfield, P. (1997) Donepezil. Drugs Aging 10, 234–239.

    Article  CAS  PubMed  Google Scholar 

  32. Anand, R., Gharabawi, G., and Enz, A. (1996) Efficacy and safety result of the early phase studies with exelon (ENA-713) in Alzheimer’s disease: an overview. J. Drug Dev. Clin. Pract. 8, 1–8.

    Google Scholar 

  33. Lahiri, D. K. and Farlow, M. R. (1996) Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J. Mol. Neurosci. 7, 41–49.

    Article  CAS  PubMed  Google Scholar 

  34. Growdon, J. (1997) Muscarinic agonists in Alzheimer’s disease. Life Sci. 60, 993–998.

    Article  CAS  PubMed  Google Scholar 

  35. Bodick, N., Offen, W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54,465–473.

    CAS  PubMed  Google Scholar 

  36. Kumar, R., on behalf of the SmithKline Beecham Alzheimer’s Disease Study Group. (1996) Efficacy and safety of SB202026 as a symptomatic treatment for Alzheimer’s disease. Ann. Neurol. 40, 504 (abstr.).

    Google Scholar 

  37. Luine, V. N. (1985) Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp. Neurol. 89, 484–490.

    Article  CAS  PubMed  Google Scholar 

  38. Gould, E., Woolley, C. S., Frankfurt, M., and McEwen, B. S. (1990) Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J. Neurosci. 10, 1286–1291.

    CAS  PubMed  Google Scholar 

  39. Toran-Allerand, C. D., Miranda, R. C., Bentham, W. D., Sohrabji, F., Brown, T. J., Hochberg, R. B., and MacLusky, N. J. (1992) Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA 89, 4668 672.

    Article  Google Scholar 

  40. Tang, M. X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., et al. (1996) Effect of estrogen during menopause on risk and age at onset of Alzheimers disease. Lancet 348, 429–32.

    Article  CAS  PubMed  Google Scholar 

  41. Kawas, C., Resnick, S., Morrison, A., Brookmeyer, R., Corrada, M., Zonderman, A., et al. (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimers disease. Neurology 48, 1517–1521.

    CAS  PubMed  Google Scholar 

  42. Asthana, S., Craft, S., Baker, L. D., et al. (1996) Transdermal estrogen improves memory in women with Alzheimer’s disease. Soc. Neurosci. Abstr. 22, 200.

    Google Scholar 

  43. Shumaker, S. and Rapp, S. (1996) Hormone therapy in dementia prevention: the Womens Health Initiative memory study. Neurobiol. Aging 17(Suppl. 4s), S9.

    Article  Google Scholar 

  44. Breitner, J. C. S., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., and Anthony, J. C. (1994) Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control. study. Neurology 44, 227–232.

    CAS  Google Scholar 

  45. Andersen, K., Launer, L. J., Ott, A., Hoes, A. W., Breteler, M. M., and Hofman, A. (1995) Do nonsteriodal anti-inflammatory drugs decrease the risk for Alzheimer’s disease. Neurology 45,1441–1445.

    CAS  PubMed  Google Scholar 

  46. McGeer, P. L., Schulzer, M., and McGeer, E. G. (1996) Arthritis and anti-inflam-matory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 47,425–32.

    CAS  PubMed  Google Scholar 

  47. Stewart, W. F., Kawas, C., Corrada, M., and Metter, E. J. (1997) Risk of Alzheimer’s disease and duration of NS AID use. Neurology 48, 626–632.

    CAS  PubMed  Google Scholar 

  48. Aisen, P. S., and Davis, K. L. (1997) The search for disease-modifying treatment for Alzheimers disease. Neurology 48(Suppl. 6), S35–S41.

    CAS  PubMed  Google Scholar 

  49. Lue, L. F., Brachova, L., Civin, W. H., and Rogers, J. (1996) Inflammation, Aβ deposition and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J. Neuropathol. Exp. Neurol. 55,1083–1088.

    CAS  PubMed  Google Scholar 

  50. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., et al. (1996) RAGE and amyloid-peptide neurotoxicity in Alzheimer’s disease. Nature 382,685–691.

    Article  CAS  PubMed  Google Scholar 

  51. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., et al. (1993) Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43, 1609–1611.

    CAS  PubMed  Google Scholar 

  52. Zeidler, H. (1991) Epidemiology of NSAID induced gastropathy. J. Rheumatol. 18(Suppl. 28), S2–S5.

    Google Scholar 

  53. Smith, W. L. and DeWitt, D. L. (1995) Biochemistry of prostaglandin endoperox-ide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol. 15, 179–194.

    CAS  PubMed  Google Scholar 

  54. Seibert, K., Masferrer, J., Zhang, Y., Gregory, S., Olson, G., Hauser, S., et al. (1995) Mediation of inflammation by cyclo-oxygenase-2. Agents Actions Suppl. 46,41–50.

    CAS  PubMed  Google Scholar 

  55. Nogawa, S., Zhang, F., Ross, M. E., and Iadecola, C. (1997) Cyclo-oxyge-nase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17, 2746–2755.

    CAS  PubMed  Google Scholar 

  56. Palmer, A. M. and Burns, M. A. (1994) Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimers disease. Brain Res. 645, 338–342.

    Article  CAS  PubMed  Google Scholar 

  57. Mecocci, P., MacGarvey, U., and Beal, M. F. (1994) Oxidative damage to mitochondrial DNAis increased in Alzheimers disease. Ann. Neurol. 36,747–751.

    Article  CAS  PubMed  Google Scholar 

  58. Hensley, K., and Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., et al. (1995) Brain regional correspondence between Alzheimer’s disease histo-pathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146–2156.

    Article  CAS  PubMed  Google Scholar 

  59. Smith, M. A. and Perry, G. (1995) Free radical damage, iron and Alzheimer’s disease. J. Neurol. Sci. 134(Suppl.), 92–94.

    Article  PubMed  Google Scholar 

  60. Christen, S., Woodall, A.A., Shigenaga, M. K., Southwell-Keely, P. T., Duncan, M. W., and Ames, B. N. (1997) Gamma-tocopherol. traps mutagenic electrophiles such as NO(X) and complements α-tocopherol: physiological implications. Proc. Natl. Acad. Sci. USA 94, 3217–3222.

    Article  CAS  PubMed  Google Scholar 

  61. Behl, C., Davis, J., Cole, G. M., and Schubert, D. (1992) Vitamin E protects nerve cells from amyloid-protein toxicity. Biochem. Biophys. Res. Commun. 186, 944–950.

    Article  CAS  PubMed  Google Scholar 

  62. Olson, L., Nordberg, A., von Holst, H., Backman, L., Ebendal, T., Alafuzoff, I., et al. (1992) Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural. Transm. Park Dis. Dement. Sect. 4,79–95.

    Article  CAS  PubMed  Google Scholar 

  63. Yamada, K., Nitta, A., Hasegawa, T., Fuji, K., Hiramatsu, M., Kameyama, T., et al. (1997) Orally active NGF stimulators: potential therapeutic agents in Alzheimers disease. Behav. Brain Res. 83, 117–122.

    Article  CAS  PubMed  Google Scholar 

  64. McRae, A., Rudolphi, K. A., and Schubert, P. (1994) Propentopylline depresses amyloid and Alzheimer’s CSF microglial antigens after ischaemia. NeuroReport 5, 1193–1196.

    CAS  PubMed  Google Scholar 

  65. Nitta, A., Hasegawa, T., and Nabeshima, T. (1993) Oral administration of idebenone, a stimulator of NGF synthesis recovers reduced NGF content in aged rat brain. Neurosci. Lett. 163, 219–222.

    Article  CAS  PubMed  Google Scholar 

  66. Bruno, V., Battaglia, G., Copani, A., Sortino, M. A., Canonico, P. L., and Nicoletti, F. (1994) Protective action of idebenone against excitotoxic degen-eration in cultured cortical neurons. Neurosci. Lett. 178, 193–196.

    Article  CAS  PubMed  Google Scholar 

  67. Wieland, E., Schutz, E., Armstrong, V. W., Kuthe, F., Heller, C., and Oellerich, M. (1995) Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions. Transplantation 60, 444–51.

    Article  CAS  PubMed  Google Scholar 

  68. Weyer, G., Erzigkeit, H., Hadler, D., and Kubicki, S. (1996) Efficacy and safety of idebenone in the long-term treatment of Alzheimer’s disease-a double-blind, placebo controlled multicentre study. Hum. Psychopharmacol. 11, 53–65.

    Article  CAS  Google Scholar 

  69. Weyer, G., Babejdolle, R. M., Hadler, D., Hofmann, S., and Herrmann, W. M. (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 36, 73–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Minnesota Medical School, Minneapolis, MN

    David S. Knopman

Authors
  1. David S. Knopman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Leeds, Leeds, UK

    Nigel M. Hooper

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Knopman, D.S. (2000). Advances in Methodology and Current Prospects for Primary Drug Therapies for Alzheimer's Disease. In: Hooper, N.M. (eds) Alzheimer's Disease. Methods in Molecular Medicine™, vol 32. Humana Press. https://doi.org/10.1385/1-59259-195-7:45

Download citation

  • DOI: https://doi.org/10.1385/1-59259-195-7:45

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-737-3

  • Online ISBN: 978-1-59259-195-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation